Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CG Oncology, Inc. (CGON – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CG Oncology, Inc. (CGON)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on CG Oncology, Inc. today and set a price target of $65.00. The company’s shares closed last Thursday at $53.07.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Currently, the analyst consensus on CG Oncology, Inc. is a Strong Buy with an average price target of $76.67, a 36.4% upside from current levels. In a report issued on January 12, Goldman Sachs also maintained a Buy rating on the stock with a $82.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Disc Medicine (IRON)
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Disc Medicine. The company’s shares closed last Thursday at $71.04.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $121.10 average price target, a 67.1% upside from current levels. In a report issued on January 8, Morgan Stanley also maintained a Buy rating on the stock with a $120.00 price target.
